Publication
Long-term outcomes of azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3-mutated AML.
Nicholas J Short, Hagop Kantarjian, Naval Daver, Roberta S Azevedo, Omer Karrar, Courtney D DiNardo, Tapan Kadia, Musa Yilmaz, Manuel Maroun, Maria Hachem, Gautam Borthakur, Ghayas C Issa, Elizabeth J Shpall, Uday Popat, Xuelin Huang, Wei Qiao, Lewis Nasr, Walid Macaron, Regina Abramova, Guillermo Garcia-Manero, Marina Konopleva, Farhad Ravandi
- Source
- PubMed
- Retrieved
- Sep 19, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260919-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Among patients with FLT3-mutated acute myeloid leukemia (AML) who receive frontline azacitidine plus venetoclax, relapses are commonly driven by the expansion of the FLT3-mutated clone, supporting FLT3 inhibitor-based triplet lower-intensity regimens. We report long-term outcomes of a phase 2 study…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 1
- trialNCT04140487registry_reference1.00
Registered trialsNCT04140487
Curated evidence
Evidence citing this paper (0)
Data not yet available